Abstract
Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC. The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients. Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT). Results: Four median cycles of chemotherapy were administered; the most common severe toxicity was neutropenia (37.5%). An overall response rate of 50% was observed; 4.2% of patients achieved complete response and 45.8% partial response. No opportunistic infections occurred during or immediately after chemotherapy. The medi+ count was 380 (range 220-570) at diagnosis. Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Moreover, the concomitant use of HAART did not seem to increase the FOLFOX4 toxicity. This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART.
Keywords: Metastatic Colorectal Cancer, FOLFOX4, HIV-infection, HAART, chemotherapy, treatment
Current HIV Research
Title: Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection
Volume: 8 Issue: 3
Author(s): Massimiliano Lanzafame, Umberto Tirelli, Lorenza Guella, Annalisa Ridolfo, Elisa Garlassi, Clara Schiantarelli, Rossella Fisichella, Salvatore Berretta, Francesco Basile, Guglielmo Nasti, Massimiliano Berretta, Immacolata Izzi, Vincenzo Montesarchio, Giuseppe Nunnari, Bruno Cacopardo, Renato Talamini, Michele Spina, Alessandra Bearz, Alessandro Cappellani and Arben Lleshi
Affiliation:
Keywords: Metastatic Colorectal Cancer, FOLFOX4, HIV-infection, HAART, chemotherapy, treatment
Abstract: Background: Although FOLFOX4 is considered the standard chemotherapy regimen for colorectal cancer (CRC), few data are available on its results in human immunodeficiency (HIV)-related CRC. The results were analyzed to evaluate feasibility and activity of FOLFOX4 plus highly active antiretroviral therapy (HAART) in metastatic CRC (mCRC) HIV-seropositive patients. Patients and Methods: From January 2002 to March 2007, 24 patients were selected among the CRC HIV-seropositive patients treated with FOLFOX4 and concomitant HAART within the Italian Cooperative Group on AIDS and Tumors (GICAT). Results: Four median cycles of chemotherapy were administered; the most common severe toxicity was neutropenia (37.5%). An overall response rate of 50% was observed; 4.2% of patients achieved complete response and 45.8% partial response. No opportunistic infections occurred during or immediately after chemotherapy. The medi+ count was 380 (range 220-570) at diagnosis. Conclusions: To our knowledge, this is the largest study describing activity and tolerability of FOLFOX4 and HAART, in this setting. FOLFOX4 plus concomitant HAART resulted feasible and active also in HIV-seropositive patients. Moreover, the concomitant use of HAART did not seem to increase the FOLFOX4 toxicity. This study suggests the good tolerability of the FOLFOX4, making it a reasonable option for combination with HAART.
Export Options
About this article
Cite this article as:
Lanzafame Massimiliano, Tirelli Umberto, Guella Lorenza, Ridolfo Annalisa, Garlassi Elisa, Schiantarelli Clara, Fisichella Rossella, Berretta Salvatore, Basile Francesco, Nasti Guglielmo, Berretta Massimiliano, Izzi Immacolata, Montesarchio Vincenzo, Nunnari Giuseppe, Cacopardo Bruno, Talamini Renato, Spina Michele, Bearz Alessandra, Cappellani Alessandro and Lleshi Arben, Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection, Current HIV Research 2010; 8 (3) . https://dx.doi.org/10.2174/157016210791111061
DOI https://dx.doi.org/10.2174/157016210791111061 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
HIV Vaccine Development.
The development of a safe and effective vaccine that impedes HIV-1 transmission and/or limits the severity of infection remains a public health priority. The HIV-1/AIDS pandemic continues to have a disproportionate impact on vulnerable and under-served communities in the USA and globally. In the USA, minority communities that have relatively ...read more
Lymphomas in People Living with HIV (PLWH)
In the era of combined antiretroviral therapy (cART), the incidence of lymphoma among people living with HIV (PLWH) surpassed Kaposi's sarcoma in 2011, becoming the most common AIDS-defining malignancy. The annual incidence rate ranges approximately from 100 to 300 per 100,000 individuals with HIV infection as the population denominator, which ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lessons in Medical Record Abstraction from the Prostate, Lung, Colorectal, and Ovarian (PLCO) National Screening Trial
Reviews on Recent Clinical Trials Endogenous and Exogenous Natural Adjuvants for Vaccine Development
Mini-Reviews in Medicinal Chemistry DNA Double Strand Break Repair - Related Synthetic Lethality
Current Medicinal Chemistry Metallocarboxypeptidases: Emerging Drug Targets in Biomedicine
Current Pharmaceutical Design Anti-cancer Effects of Metformin: Recent Evidences for its Role in Prevention and Treatment of Cancer
Current Drug Metabolism Magnetic Nanoparticles: A Review on Stratagems of Fabrication an d its Biomedical Applications
Recent Patents on Drug Delivery & Formulation The Combination of FDG PET/CT and Contrast Enhanced CT in the Evaluation of Recurrent Pancreatic Carcinoma and Cholangiocarcinoma
Current Medical Imaging miR-4319 Suppresses the Growth of Esophageal Squamous Cell Carcinoma Via Targeting NLRC5
Current Molecular Pharmacology Protein-Based HIV-1 Microbicides
Current HIV Research Using Cheminformatics for the Identification of Biological Functions of Small Molecules in Metabolic Pathway
Current Topics in Medicinal Chemistry MUC1 is a Promising Therapeutic Target for Prostate Cancer Therapy
Current Cancer Drug Targets Interleukin-6: A Critical Cytokine in Cancer Multidrug Resistance
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) Inhibition - A Critical Review
Anti-Cancer Agents in Medicinal Chemistry Targeting IGF-I, IGFBPs and IGF-I Receptor System in Cancer: The Current and Future in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery An Overview of C19MC Cluster Subgroup 3 and Cancer
MicroRNA Identification of Disease-Relevant Genes for Molecularly-Targeted Drug Discovery
Current Cancer Drug Targets MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Withdrawal Notice: Emerging Biomarkers and Contributing Factors of Prostate Cancer
Current Cancer Therapy Reviews Epigenome-Wide Association Studies (EWAS) in Cancer
Current Genomics Coupling Caspase Cleavage and Proteasomal Degradation of Proteins Carrying PEST Motif
Current Protein & Peptide Science